



THOMSON MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

RESPONSE TO THE COVID-19 PANDEMIC

The Board of Directors of Thomson Medical Group Limited (the “**Company**” or “**TMG**”, together with its subsidiaries, the “**Group**”) wishes to give an update on the Group’s response to the COVID-19 situation. On 12 February 2020, the Group’s financial results for the year ended 31 December 2019 noted that “the current 2019 Novel Coronavirus cases are growing albeit with smaller numbers in Singapore and Malaysia, the epidemic if it persists or deteriorates to a pandemic, may affect the business of the Group especially of those elective and non-urgent cases”.

Since 12 February 2020, the environment has changed dramatically. What started out as just a novel coronavirus has now evolved into a global pandemic. In both Singapore and Malaysia, the two countries in which the Group operates in, businesses have been subjected to lockdowns of varying degrees, travel restrictions and strict social distancing measures.

To stem the spread of the virus in Singapore the government has put in place an eight-week circuit breaker, affecting the operations of most businesses, including the traditionally resilient healthcare sector. Over in Malaysia, the enforcement of the Movement Control Order (“MCO”) has also seen economic activity slowing down significantly.

While demand for the Group’s obstetric services in Singapore remains healthy, several of our services and satellite clinics remain closed with others operating under significantly restricted conditions. In Malaysia, the MCO has impacted patient loads at the hospital and fertility operations, as affected parties are compelled to postpone non-emergency treatment.

Without a vaccine or a definitive cure, the unpredictable and fluid nature of the COVID-19 pandemic is here to stay for some time yet. The Group expects obstetric services in Singapore to remain healthy while demand for some of our services across the Group to gradually pick up when control measures are progressively relaxed in a step-wise manner in the locations in which the Group operates and derive its patients from.

The Group’s top priorities are to ensure the safety of our patients and staff, and the viability of the business while at the same time protecting employees’ jobs. Taking pre-emptive steps to meet these priorities, TMG’s senior management has volunteered to forgo their annual wage increment, performance bonus, and annual wage supplement (i.e. “13th month”) this year, while the Board has voluntarily cut their directors’ fees by 20 per cent with effect from 1 June 2020. On top of adopting other cost cutting measures, the Group continues to fine-tune daily operations and strategies along with the evolving business environment.

Despite these unprecedented challenges, the Group is committed to ensuring the safety, health and wellbeing of our patients, employees and other stakeholders, while we continue to operate in this new normal.

Should there be other substantive updates, the Group will provide shareholders with further relevant announcements as they happen.

By Order of the Board
THOMSON MEDICAL GROUP LIMITED

Dr Wong Chiang Yin
Executive Director and Group Chief Executive Officer
21 May 2020